Why Vor Biopharma Inc.’s (VOR) Stock Is Up 5.87%
As of Tuesday, November 03, Vor Biopharma Inc.’s VOR share price has surged by 5.87%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 6.67%
As of Friday, October 30, Vor Biopharma Inc.’s VOR share price has dipped by 6.67%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 6.93%
As of Tuesday, October 20, Vor Biopharma Inc.’s VOR share price has surged by 6.93%, which has investors questioning if this is right time to sell.Michael Rose
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 5.64%
As of Friday, October 16, Vor Biopharma Inc.’s VOR share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 6.08%
As of Thursday, October 15, Vor Biopharma Inc.’s VOR share price has surged by 6.08%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | VOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,182.6 | $223.5 | 48% |
|
| Shares Out (Mil) | 59.7 | 53.4 | 51% |
|
| Institutional Ownership | 96.9% | 92.9% | 71% |
|
| Float (Mil) | 37.2 | 40.4 | 40% |
|
| Beta | 1.78 | 0.96 | 88% |
|
| Avg Daily Volume (000s) | 767 | 463 | 65% |
|
| Price Change (52-week) |
(23.0%) | 45.9% | 34% |
|
| Growth | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (74.3%) | (10.1%) | 4% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (61.9%) | (15.7%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.813) | ($6.020) | ($3.534) | |
| Month Ago EPS | ($0.953) | ($6.530) | ($3.815) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.933) | ($6.901) | ($3.742) | |
| Year/Year Chg | (44.0%) | (91.5%) | (94.1%) | |
| Financials | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $1,354 | ($44) | 89% |
|
| EPS (TTM) | $30.513 | ($1.600) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | ($119) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($82) | $2 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $730 | $173 | 37% |
|
| Valuation | VOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.08 | na |
|
| P/E | 0.6 | 20.2 | 0% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | 402.6% | (47.0%) | 100% |
|
| ROE | (114.6%) | (52.7%) | 8% |
|
| Liabilities to Assets | 127.6% | 29.6% | 97% |
|
| F-Score | 3 | 2 | 18% |
|
Vor Biopharma Inc. did not pass any screens on 11/2/2026.
